To own Roche, you have to believe its broad pharma and diagnostics portfolio can offset China pricing pressure, biosimilar erosion after 2026, and uneven trial outcomes. The TIGIT and Ibex AI developments support the existing precision oncology and diagnostics catalyst, but they do not materially change the near term focus on upcoming earnings and execution in China and late stage R&D.<\/p>\n
The recent FDA approval of the PATHWAY anti HER2\/neu (4B5) antibody and VENTANA HER2 Dual ISH tests for ENHERTU adds another concrete step in companion diagnostics, directly tying into Roche\u2019s precision oncology and AI enabled biomarker ambitions highlighted by the Ibex announcement.<\/p>\n
Yet behind the promise of TIGIT and AI pathology tools, investors should still be aware of the risk that…<\/p>\n
Read the full narrative on Roche Holding (it’s free!)<\/a><\/p>\n Roche Holding’s narrative projects CHF67.3 billion revenue and CHF16.8 billion earnings by 2028. This requires 1.9% yearly revenue growth and a CHF7.4 billion earnings increase from CHF9.4 billion today.<\/p>\n Uncover how Roche Holding’s forecasts yield a CHF323.28 fair value<\/a>, in line with its current price.<\/p>\n Eight Simply Wall St Community fair value estimates span roughly CHF302 to CHF732 per share, so you see very different expectations for Roche\u2019s potential. Set these views against Roche\u2019s reliance on oncology pipeline progress and AI enabled diagnostics to offset China pricing and upcoming biosimilar pressure, and you can decide which assumptions about its future performance feel most realistic.<\/p>\n Explore 8 other fair value estimates on Roche Holding<\/a> – why the stock might be worth 8% less than the current price!<\/p>\n Disagree with existing narratives? Create your own in under 3 minutes<\/a> – extraordinary investment returns rarely come from following the herd.<\/p>\n Our daily scans reveal stocks with breakout potential. Don’t miss this chance:<\/p>\n This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.<\/p>\n Companies discussed in this article include ROG.SW<\/a>.<\/p>\n Have feedback on this article? Concerned about the content? Get in touch<\/a> with us directly. Alternatively, email editorial-team@simplywallst.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"In recent developments, Roche has featured prominently in the race to develop TIGIT inhibitors for cancer immunotherapy, while…\n","protected":false},"author":2,"featured_media":18683,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[19993,6718,14235,134],"class_list":["post-33774","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-biomarker-development","tag-cancer-immunotherapy","tag-companion-diagnostics","tag-roche"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116244590343232475","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/33774","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=33774"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/33774\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/18683"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=33774"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=33774"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=33774"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}![\"SWX:ROG](\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/02\/5fa3f657d5eb264beb4ead44c4fddedf.png\")
<\/a> SWX:ROG 1-Year Stock Price Chart <\/p>\n